The Exchange had sought clarification from JHS Svendgaard Laboratories Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The National Stock Exchange raised queries with JHS Svendgaard Laboratories under SEBI Listing Regulation 33, flagging discrepancies in the company's Q2 FY2025 financial results (quarter ended September 2025) filed on 14 November 2025. The issues identified were an incorrect Board Meeting end time recorded in the NSE portal (NEAPS) and inaccurate EPS figures in the original submission. The company responded by filing revised Integrated Financial Results on 29 April 2026 to correct both errors. The company has requested NSE to treat the revised submission as the valid filing and the matter as complied with. The response was submitted by the Company Secretary and Compliance Officer.
The stock may face minor selling pressure or scrutiny due to revised financials, but since the company proactively corrected the errors and responded to the exchange query, the impact on the stock is likely to be limited and short-lived.